Search results
Showing 76 to 90 of 1257 results for pathway
Pentosan polysulfate sodium for treating bladder pain syndrome (TA610)
Evidence-based recommendations on pentosan polysulfate sodium (Elmiron) for bladder pain syndrome in adults.
Developmental follow-up of children and young people born preterm (QS169)
This quality standard covers the developmental follow-up of babies, children and young people under 18 years who were born preterm (before 37+0 weeks of pregnancy). It describes high-quality care in priority areas for improvement.
This quality standard covers providing and organising services for people with sarcoma. It includes pathways for referral and diagnosis, treatment and support for adults, young people and children with sarcoma. It describes high-quality care in priority areas for improvement.
View quality statements for QS78Show all sections
Sections for QS78
- Quality statements
- Quality statement 1: Diagnostic pathways
- Quality statement 2: Multidisciplinary teams for sarcoma
- Quality statement 3: Publishing information about areas of expertise
- Quality statement 4: Retroperitoneal sarcoma
- Quality statement 5: Surgical skills
- Quality statement 6: Key workers
- Update information
Healthcare-associated infections: prevention and control (PH36)
This quality improvement guide was produced by NICE, in partnership with Public Health England (PHE). Its aim is twofold: to reduce the risk of harm from healthcare-associated infections for patients, staff and visitors; and to reduce the costs associated with preventable infection.
Show all sections
Sections for PH36
- Overview
- Introduction
- Quality improvement statement 1: Board-level leadership to prevent HCAIs
- Quality improvement statement 2: Be a learning organisation
- Quality improvement statement 3: HCAI surveillance
- Quality improvement statement 4: Workforce capacity and capability
- Quality improvement statement 5: Environmental cleanliness
- Quality improvement statement 6: Multi-agency working to reduce HCAIs
This quality standard covers assessing and managing hearing loss in adults (aged 18 and over). It includes people presenting with hearing loss for the first time in adulthood whether it started in adulthood or earlier. It describes high-quality care in priority areas for improvement.
View quality statements for QS185Show all sections
Sections for QS185
- Quality statements
- Quality statement 1: Earwax removal
- Quality statement 2: Sudden onset of hearing loss
- Quality statement 3: Rapid worsening of hearing loss
- Quality statement 4: Audiological assessment
- Quality statement 5: Provision of hearing aids
- Quality statement 6: Follow-up audiology appointment
- About this quality standard
Evidence-based recommendations on carfilzomib (Kyprolis) for previously treated multiple myeloma in adults.
Larotrectinib for treating NTRK fusion-positive solid tumours (TA630)
Evidence-based recommendations on larotrectinib (Vitrakvi) for treating neurotrophic tyrosine receptor kinase (NTRK) fusion-positive solid tumours in adults and children.
NICE Advice works closely with our system partners and industry to drive innovation into the hands of health and care professionals, to enable best practice.
Pembrolizumab for adjuvant treatment of resected stage 2B or 2C melanoma (TA837)
Evidence-based recommendations on pembrolizumab (Keytruda) for the adjuvant treatment of resected stage 2B and 2C melanoma in people 12 years and over.
Filgotinib for treating moderate to severe rheumatoid arthritis (TA676)
Evidence-based recommendations on filgotinib (Jyseleca) for moderate to severe rheumatoid arthritis in adults.
Cenobamate for treating focal onset seizures in epilepsy (TA753)
Evidence-based recommendations on cenobamate (Ontozry) for treating focal onset seizures with or without secondary generalised seizures in adults with drug-resistant epilepsy that has not been adequately controlled with at least 2 antiseizure medicines.
Endo-SPONGE for treating low rectal anastomotic leak (HTG605)
Evidence-based recommendations on Endo-SPONGE for treating low rectal anastomotic leak.
Digital technologies for managing non-specific low back pain: early value assessment (HTG712)
Early value assessment (EVA) guidance on digital technologies for managing non-specific low back pain in people 16 years and over.
Carfilzomib with dexamethasone and lenalidomide for previously treated multiple myeloma (TA695)
Evidence-based recommendations on carfilzomib (Kyprolis) with dexamethasone and lenalidomide (Revlimid) for previously treated multiple myeloma in adults.
Evidence-based recommendations on infliximab (Remicade, Inflectra or Remsima), adalimumab (Humira) and golimumab (Simponi) for treating moderate to severe ulcerative colitis in adults, and on infliximab for treating severe active ulcerative colitis in children and young people of 6–17 years.